MSP-4019

MSP-4019 is a **preclinical small-molecule psychedelic drug candidate** discovered by **Mindset Pharma** as part of its Family 4 program of **DMT and 5-MeO-DMT-inspired next-generation compounds**. It was being explored for **neurological and psychiatric disorders** within the broader nervous system disease area. Publicly available information indicates **strong activity in the mouse head-twitch assay**, consistent with psychedelic pharmacology, and an **improved preclinical safety profile** versus first-generation comparators, including no reported signs of **5-HT syndrome** at doses up to 30 mg/kg in disclosed studies. The precise molecular target profile has not been explicitly disclosed, but based on the compound class it is most plausibly intended to act through **serotonergic psychedelic receptor pharmacology**, likely centered on **5-hydroxytryptamine receptor signaling**. The program's highest reported R&D status is **discontinued**.